35 results about "Choroid blood vessels" patented technology

The invention discloses a choroid vessel segmentation method and system based on a three-dimensional coherent tomographic image. The method includes the steps of collecting the three-dimensional frequency domain coherent optical tomographic image; calculating a fundus radian model according to the space size represented by a single voxel point in the three-dimensional frequency domain coherent optical tomographic image and the actual size of the image; segmenting a retinal base Bruch's membrane from the fundus radian model by using a single-layer graph searching method; calculating the space tensor of each voxel point so as to obtain the point probability of the voxel point in a choroid vessel, and screening out a pre-selected area of the choroid vessel with the point probability value larger than zero; selecting out a point probability value larger than 75% and a point probability value less than 25% from the pre-selected area of the choroid vessel to serve as the high and low thresholds of the pre-selected area growth, so as to obtain the initial segmentation of the foreground and background of the initial segmentation of the choroid vessel, and solving the optimal model of a structure diagram according to the foreground and background of the choroid vessel to obtain the accurate segmentation of the choroid vessel.

The invention discloses a choroid three-dimensional blood vessel imaging and quantitative analysis method and device based on an optical coherence tomography system. Reverse compensation is performedon a deep choroid blood vessel and a matrix, which are obtained by OCT, through a backward scattering attenuation signal based on the idea of OCT backward scattering signal reverse compensation, and the signal-to-noise ratio of the choroid blood vessel is improved; after an enhanced OCT choroid image signal is acquired, a segmentation method based on deep learning is further adopted to perform intelligent segmentation on boundaries between a choroid and a retina epithelium and between the choroid and a sclera, and the defects that a traditional algorithm consumes time and is low in accuracy inthree-dimensional choroid boundary segmentation are overcome; and, on the basis of boundary segmentation, an improved self-adaptive threshold segmentation method is further adopted to automatically separate three-dimensional choroidal vessels from non-vascular tissues, and global and regional quantitative indexes capable of representing choroidal ischemia are calculated according to the distribution and proportion of the vessels in the image in a three-dimensional body space.

The invention relates to the field of biomedical image processing, in particular to a choroidal angiography method based on optical coherence tomography imaging body scanning. The method can be widelyused for screening and diagnosis of medical ophthalmic diseases. The method includes the steps of S1, acquiring original data of OCT body scanning fundus; S2, extracting retinal blood vessel shadow data and choroidal blood vessel data from the original data; S3, using the retinal blood vessel shadow data for masking the choroidal blood vessel data to obtain choroidal angiography data. According to the technical scheme above, by extracting the retinal blood vessel shadow data to mask the choroidal blood vessel data, retinal blood vessel shadows in the choroidal blood vessel data are removed, so that the influence of the retinal blood vessel shadows on the contrast and continuity of choroidal blood vessel projection images is reduced, and choroidal vessels can be completely and clearly displayed.

This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.

A method of tightening inter-cellular junctions in retinal or choroidal vessel cells includes exposing the retinal or choroidal vessel cells to norrin. Upon sufficient contact time, for norrin to selectively up-regulate gene expression of VE-cadherin or claudin-5 in the retinal or choroidal vessel cells, the inter-cellular junctions are tightened. The method is also suitable for treating retinal pigment epithelial cells in wet macular degeneration.

The invention relates to a method for evaluating and optimizing blood vessel photodynamic therapeutic effects of different light dosages on the same experimental animal, in particular to therapeutic effects of a photodynamic method is used for treating vascular disease, such as nevus flammeus and choroidal vessels, and the method can be used for evaluating and optimizing illumination parameters of a pulse dye laser and other photo-thermal therapy for treating the vascular disease. According to the method, structured light irradiation with preset dosage is performed on the same experimental animal, and the method comprises the main steps of sample dissecting and dyeing, sample slicing and three-dimensional reconstructing, and experimental data analyzing and evaluating, thereby obtaining the therapeutic evaluations of different light dosages on the same experimental animal. Through the method, clinical experiment animals can be greatly reduced, the evaluations of therapeutic effects of blood vessels in different depths and diameters can be provided, and the determination of the optimal illumination dosage is accelerated.

The invention relates to ophthalmic formulations of squalamine or its pharmaceutically acceptable salts for the treatment of conditions of the eye such as, for example, wet age-related macular degeneration (wet AMD), choroidal neovascularization, retinopathy, dry age-related macular degeneration (dry AMD), polypoidal choroidal vasculopathy, neovascularization following ocular surgery, macular edema, retinal venous occlusion, subchoroidal neovascularization, retinal epithelial detachment, pterygum or foveal geographic atrophy of the retinal pigment epithelium.

The invention discloses a method for measuring the diameter of the maximum choroid blood vessel based on image segmentation. The method comprises the following steps: firstly performing image pre-processing on a choroid in a SD-OCT retina image, then adopting the method of image segmentation to extract a region of interest and performing related calculation on the region, and finally outputting a measuring result. According to the invention, the method reduces measuring errors by making the obtained diameter of the choroid maximum blood vessel with an improved precision than the diameter obtained by manual measuring. The method, by using the simple and rapid image segmentation technology, increases accuracy and efficiency in measuring the diameter of the choroid blood vessel, and has great significance in facilitating successive choroid diseases analysis and improving doctor's working efficiency.

The invention relates to the field of artificial intelligence, and provides a choroidal vessel lumen area recognition method, device and equipment and a medium. The method comprises the steps of obtaining a fundus image to be recognized; inputting a fundus segmentation model based on U-Net, and performing choroidal feature extraction and edge segmentation on the fundus image to be recognized through the fundus segmentation model to obtain a fundus segmentation image; recognizing a foveal area in the fundus segmentation image through a fundus foveal recognition model, and intercepting a first fundus choroid image from the fundus segmentation image according to the foveal area; carrying out binarization processing on the first fundus choroidal image through a Niback local threshold algorithmto obtain a first choroidal binary image, and extracting a first lumen area from the first choroidal binary image; and identifying the first lumen region image. According to the invention, the funduschoroidal vessel lumen area in the fundus image can be automatically identified. The invention is suitable for the field of smart medical treatment, and can further promote the construction of smartcities.

The present invention provides new methods of treating wet type of age related macular degeneration by administering adiponectin (APN) or a functional fragment derived therefrom. One of the pathological complications of age related macular degeneration (AMD) is choroidal angiogenesis or choroidal neovascularization (CNV). The inventors discovered that the level of APN expression is significantly lower in the choroids of the laser-induced mouse model of choroidal angiogenesis or choroidal neovascularization (CNV) than that of the control mice and that administration of recombinant adiponectin (rAPN) or a peptide derived from the globular domain of the intact APN protein to the mouse model of CNV reduced the size of CNV significantly. These studies are the first to demonstrate the inhibitory effect of adiponectin on choroidal angiogenesis and thus provide the basis for treating a condition or disease involving angiogenesis, particularly age related macular degeneration, with administration of adiponectin.

The invention discloses a choroidal OCT image enhancement method and device based on signal reverse compensation. After a choroid image signal acquired by a system is preprocessed, a reverse signal attenuation compensation model is established based on the idea of OCT back scattering signal reverse compensation, the choroid signal is reversely compensated, and the signal-to-noise ratio between a blood vessel and a non-blood vessel tissue is enhanced, so that the defect that the boundary of a choroid blood vessel OCT image is difficult to segment is overcome.

The present invention provides a biomarker for detecting and diagnosing polypoidal choroidal vasculopathy (PCV) of human eyes, including levels of hyperhomocysteinemia that are identified, wherein elevated levels of hyperhomocysteinemia are highly associated with PCV of the human eyes. In addition, the present invention further provides a method for detecting and diagnosing PCV of the human eyes.

Provided is a nanoparticle-vitreous body-based protein complex, and more particularly, to a composition for inhibiting angiogenesis which includes the complex as an active ingredient, and a composition for preventing or treating an angiogenesis-related disease or a retinal disease. When the nanoparticle-vitreous body-based protein complex according to the subject matter is locally injected into the vitreous body, the complex exhibits significantly excellent binding strength with a vascular endothelial growth factor and thus can inhibit angiogenesis, thus being easily used to prepare a therapeutic agent for preventing, alleviating, or treating retinal and choroidal angiogenesis-related diseases.

The invention discloses a choroid sublayer and choroid vessel segmentation network model and a training method thereof, and the model comprises a sharing encoder module which is used for carrying out the down-sampling and feature extraction of a to-be-segmented image, and obtaining a first sharing feature; the shared decoder module is used for acquiring a first shared feature and performing up-sampling to obtain a second shared feature; the first decoder module is used for extracting choroid sublayer segmentation specific features in the second shared features; the second decoder module is used for extracting choroidal blood vessel segmentation specific features in the second shared features; and the classification module is used for calculating a segmentation result of the to-be-segmented image according to the second shared feature, the choroid sublayer segmentation specificity feature and the choroid blood vessel segmentation specificity feature. According to the invention, segmentation of choroid sublayers and choroid blood vessels is realized by arranging the five modules, namely, multi-task segmentation is realized through a multi-stream network structure.

The present invention provides a biomarker for detecting and diagnosing polypoidal choroidal vasculopathy (PCV) of human eyes, including levels of hyperhomocysteinemia that are identified, wherein elevated levels of hyperhomocysteinemia are highly associated with PCV of the human eyes. In addition, the present invention further provides a method for detecting and diagnosing PCV of the human eyes.

The invention provides a method and a preparation for regulating a complement system. An activation of the complement system is inhibited by inhibiting PDGF-D expression. The PDGF-D has a certain regulation effect on functions of the complement system, for example, when the PDGF-D is in an overexpression state, related genes (such as C1q and C3) of a complement pathway are up-regulated, such that inflammatory response is promoted and choroidal angiogenesis is induced. By inhibiting the overexpression of the PDGF-D, the activation of the complement system can be effectively inhibited, and further choroidal neovascularization and activation and migration of inflammatory cells are remarkably reduced.

This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.

The present invention relates to novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity. These compounds are useful as therapeutic agents for diseases associated with neovascularization, particularly, as therapeutic agents for cancer, rheumatoid arthritis, age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, polypoidal choroidal vasculopathy, diabetic macular edema, plaque psoriasis, atherosclerosis, and the like.

A method of tightening inter-cellular junctions in retinal or choroidal vessel cells includes exposing the retinal or choroidal vessel cells to norrin. Upon sufficient contact time, for norrin to selectively up-regulate gene expression of VE-cadherin or claudin-5 in the retinal or choroidal vessel cells, the inter-cellular junctions are tightened. The method is also suitable for treating retinal pigment epithelial cells in wet macular degeneration.

The present disclosure relates to an apparatus for angiographic optical coherence tomography in the retina or the choroid, and a method for diagnosing diseases by using the same and, more specifically, to: an apparatus for angiographic optical coherence tomography in the retina and the choroid, capable of diagnosing, at an early stage, shock states or diseases such as those of sepsis by quickly and objectively recognizing the low perfusion of tissue; and a diagnostic method using the same.

The invention discloses a medicinal composition for treating macular degeneration. The medicinal composition for treating the macular degeneration comprises eight kinds of medicaments, such as astragalus, Chinese angelica, Indian buead, thunberg fritillary bulb and the like. The medicinal composition is prepared to be pharmaceutically acceptable formulations such as decoction, tablets, capsules, pills, oral liquid preparations, injection and the like by adding the conventional auxiliary materials and by the conventional process. The medicinal composition can improve and stabilize vision of age-related macular degeneration (AMD) patients, can promote bleeding absorption and can reduce macular area choroidal neovascularization (CNV) fluorescence leakage. Symptom and disease differentiation-based treatment embodies the advantage of the traditional Chinese medical science in the aspect of improving vision function. Due to the combination of fundus fluorescein angiography (FFA) examination, pathological examination and choroid blood vessel stretched preparation, the CNV can be evaluated well. According to the observation on morphological methods such as model FFA after medicament intervention, pathology, choroid blood vessel stretched preparation and the like, the medicinal composition has a good effect of inhibiting the CNV of laser induced brown Norway (BN) rats and has a certaineffect of inhibiting or stabilizing the growth of the CNV.

This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.

Provided is a nanoparticle-vitreous body-based protein complex, and more particularly, to a composition for inhibiting angiogenesis which includes the complex as an active ingredient, and a composition for preventing or treating an angiogenesis-related disease or a retinal disease. When the nanoparticle-vitreous body-based protein complex according to the subject matter is locally injected into the vitreous body, the complex exhibits significantly excellent binding strength with a vascular endothelial growth factor and thus can inhibit angiogenesis, thus being easily used to prepare a therapeutic agent for preventing, alleviating, or treating retinal and choroidal angiogenesis-related diseases.

The invention discloses a choroidal vessel segmentation method and system based on a three-dimensional coherent tomography image, which collects a three-dimensional frequency-domain coherent optical tomographic image; The fundus arc model is calculated from the actual size; the retinal base layer Bruch's membrane is segmented from the fundus arc model using a single-layer graph search method; the spatial tensor of each voxel point is calculated to obtain the point probability of the voxel point inside the choroidal vessel , screen out the pre-selected area of ​​the choroidal vessel with a point probability value greater than 0; screen out the point probability value greater than 75% and the point probability value less than 25% from the pre-selected area of ​​the choroidal vessel as the high and low thresholds for the growth of the pre-selected area, and then obtain the choroid Initial segmentation of foreground and background of blood vessels; according to the initial segmentation of foreground and background of choroidal vessels, the optimal model of the structure graph is solved to obtain accurate segmentation of choroidal vessels.

The present invention is a type of fundus camera which is one of eye examination and diagnosis equipment. A conventional color fundus camera is equipment for illuminating retinas with light of the visible band (400-640 nm), and then showing retinal lesions and diagnosing retinal diseases. The present invention relates to: a choroidal imaging fundus camera capable of photographing both a choroidal vessel and a choroidal lesion at the back of the retina with near-infrared rays having a wavelength longer than 640 nm; and a device comprising the same. A polarizing fundus camera for effectively suppressing internal reflection, of the present invention, comprises: a lighting part (10) for emitting light; a diffusion lens (20) for diffusing the light incident from the lighting part (10); a lighting lens (30) for emitting, at a predetermined emission angle, the light incident from the diffusion lens (20); a mirror (40) for reflecting the light incident from the lighting lens (30); a polarizing beam splitter (50) allowing a P-polarized light to pass therethrough and an S-polarized light to be reflected in the light incident from the mirror (40); an objective lens (60) for magnifying an image of the fundus of the eye, which has been formed by the light incident from the polarizing beam splitter (50); a short-range eyepiece (70) for reducing the image, of the fundus of the eye, having been magnified by means of the objective lens (60); a linear polarizing filter (80) allowing only the P-polarized light to pass therethrough; a narrow-band optical filter (90) filtering, from the light having passed through linear polarizing filter, the light having a band of 12 nm or less and emitted from the polarizing beam splitter (50); and an imaging device (100) using the light having passed through the narrow-band optical filter (90) so as to convert the same into an electrical signal and acquire an image, wherein the linear polarizing filter (80) respectively has a first linear polarizing filter (81) provided between the lighting part (10) and the polarizing beam splitter (50), and a second linear polarizing filter (82) provided between the polarizing beam splitter (50) and the short-range eyepiece (70).

The invention relates to ophthalmic formulations of squalamine or its pharmaceutically acceptable salts for the treatment of conditions of the eye such as, for example, wet age-related macular degeneration (wet AMD), choroidal neovascularization, retinopathy, dry age-related macular degeneration (dry AMD), polypoidal choroidal vasculopathy, neovascularization following ocular surgery, macular edema, retinal venous occlusion, subchoroidal neovascularization, retinal epithelial detachment, pterygum or foveal geographic atrophy of the retinal pigment epithelium.

The invention features methods for introducing a therapeutic cargo into a cell of a subject. Such methods include the steps of (a) contacting the cell with a purified human CSb-6 and the therapeutic cargo; and (b) contacting the cell with a purified C7, C8, and C9, thereby forming a membrane attack complex (MAC) in the membrane of the cell, facilitating entry of the therapeutic cargo into the cell. Still another method involves treating neovascularization in an eye of a subject, the method comprising the steps of (a) contacting choroidal blood vessels of the eye with a purified human CSb-6 and the therapeutic cargo; and (b) contacting the choroidal blood vessels with a purified C7, C8, and C9, thereby forming MACS in cells of the choroidal blood vessels, facilitating entry of the therapeutic cargo into the cells of the choroidal blood vessels for treating neovascularization.

This invention is directed to novel heterocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., (s) controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.

The invention discloses a choroid membrane blood vessel extraction method based on an SD-OCT retina image, and belongs to the technical field of image processing. The method comprises the following steps: firstly performing Bruch's membrane partitioning on the input SD-OCT image, then carrying out smoothing by adopting bilateral filter, finding pixel points of which the grey scale values are monotonically decreased from top to bottom in each column in a regional image below the smoothed BM, fitting the monotonically decreased pixel points by cubic interpolation values based on a triangle to obtain a binary difference image which is positioned between a fitting surface of the region below the BM region and an original image, and finally removing a small-area communicating region in a binary result to obtain a blood vessel region of a choroid membrane layer. An experiment result shows that large blood vessels of the choroid membrane layer can be better extracted, and the choroid membrane blood vessel extraction method has great significance for facilitating the subsequent retinal disease analysis and improving the working efficiency of a doctor.